Post-transcriptional Regulation of Serotonin Receptors
Project Number5R01NS035891-10
Contact PI/Project LeaderEMESON, RONALD B.
Awardee OrganizationVANDERBILT UNIVERSITY
Description
Abstract Text
DESCRIPTION (provided by applicant): Serotonin (5-hydroxytryptamine; 5-HT) is a
monoaminergic neurotransmitter that modulates numerous sensory and motor
processes as well as a wide variety of behaviors including sleep, appetite,
pain perception, locomotion, thermoregulation, hallucinations, and sexual
behavior. Recent studies from our laboratory have indicated that the function
of the 2C-subtype of serotonin receptor (5-HT2 c R) is modulated by a novel RNA
modification process referred to as RNA editing. Editing of 5-HL2cR transcripts
is responsible for the tissue-specific expression of as many as twenty-four
5-HT2cR isoforms and is proposed to represent a regulatory mechanism by which
cells modulate their response to extracellular signals by altering the efficacy
and specificity of receptor/G-protein interactions; the long term objectives of
the proposed research are to define the cellular mechanisms involved in the
regulation of serotonergic signal transduction in the central nervous system.
We propose to examine the signaling properties of distinct 5-HT2cR isoforms
using a high-throughput, cell-based assay to identify functional interactions
between 5-HT, cR isoforms and the a-subunits of several heterotrimeric
G-proteins. These studies will be extended to examine the functional responses
of other edited 5-HT2cR isoforms that are highly expressed in the rat and human
brain and to dissect the 5-HT2cR-activated signaling pathways leading to
activation of phospholipase D, mitogenactivated (MAP) kinase and rearrangements
of the actin cytoskeleton.
To examine the physiological relevance of multiple, edited 5-HT2cR isoforms,
mice capable of expressing only, a single 5-HT2CR isoform will be generated by
targeted gene modification in embryonic stem cells; the non-edited (INI) and
fully-edited (VGV) 5-HT2c R isoforms have been selected for these studies, as
they demonstrate the greatest differences in receptor: G-protein coupling
efficacy In additional to gross alterations in animal phenotype and brain
morphology, mutant mice will be examined for alterations in physiological
systems in which the 5-HT2cR has already been implicated, including
tumorigenesis, seizure activity, feeding behavior, locomotor activity and
hippocampal function.
To further examine the role of 5-HT2cR editing in cellular transformation,
NIH-3T3 cells expressing specific 5-HT2cR isoforms will be assessed for a
number of transformed cellular characteristics including increased mitogenesis,
loss of contact inhibition, loss of anchorage dependence and the ability to
generate tumors in nude mice. It is anticipated that these studies will provide
new insights concerning the regulation of cellular processes involved in the
transduction of serotonergic signals and the role(s) of multiple serotonin
receptors in the nervous system.
National Institute of Neurological Disorders and Stroke
CFDA Code
853
DUNS Number
965717143
UEI
GTNBNWXJ12D5
004413456
DWH7MSXKA2A8
Project Start Date
01-February-1997
Project End Date
31-January-2008
Budget Start Date
01-February-2006
Budget End Date
31-January-2008
Project Funding Information for 2006
Total Funding
$339,138
Direct Costs
$224,595
Indirect Costs
$114,543
Year
Funding IC
FY Total Cost by IC
2006
National Institute of Neurological Disorders and Stroke
$339,138
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01NS035891-10
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01NS035891-10
Patents
No Patents information available for 5R01NS035891-10
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01NS035891-10
Clinical Studies
No Clinical Studies information available for 5R01NS035891-10
News and More
Related News Releases
No news release information available for 5R01NS035891-10
History
No Historical information available for 5R01NS035891-10
Similar Projects
No Similar Projects information available for 5R01NS035891-10